PANACEABIO · NSE
Panacea Biotec Limited
₹367.9
-1.10% (-₹4.1)
Prev. close
₹372
Volume
1,19,782
Delivery %
44.5%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Panacea Biotec Limited
Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. It operates through Vaccines and Pharmaceutical formulations & Nutrition segments. The company's product portfolio includes prescription products in various therapeutic areas, such as oncology, diabetes, gastro-intestinal care, nephrology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, Mpox, and hepatitis A vaccines, etc. It also offers health supplement products; and paediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. In addition, the company engages in the real estate business. It exports its products to approximately 50 countries. The company has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.
Details
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Rajesh Jain Ph.D.
Headquarters
New Delhi
Employees
2,102
Website
panaceabiotec.comExchange
View on NSE ↗Key stats
Market cap
₹2,253.41 Cr
EPS (TTM)
₹-1.15
Beta (1Y · daily vs NIFTY 50)
1.08
Beta (5Y · monthly vs NIFTY 50)
1.25
Shares float
1.52 Cr
EPS · quarter ended Jun 2026
₹0.38
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (consolidated), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.7% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹624.81 Cr | ₹661.23 Cr | ₹459.95 Cr | ₹559.17 Cr | ₹559.09 Cr | ₹639.77 Cr | |
| EBITDA | ₹86.62 Cr | ₹1,673.32 Cr | ₹56.36 Cr | ₹41.77 Cr | ₹30.74 Cr | ₹31.74 Cr |
| ₹-147.65 Cr | ₹1,077.91 Cr | ₹-33.24 Cr | ₹-1.17 Cr | ₹-8.37 Cr | ₹-5.37 Cr | |
| Diluted EPS | ₹-24.11 | ₹175.98 | ₹-5.43 | ₹-0.19 | ₹-1.37 | ₹-0.88 |
Depreciation & amortisation has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,177.53 Cr | ₹1,758.87 Cr | ₹1,271.16 Cr | ₹1,240.68 Cr | ₹1,289.75 Cr | ₹1,262.17 Cr | |
| ₹819.53 Cr | ₹34.16 Cr | ₹20.22 Cr | ₹15.00 Cr | ₹15.00 Cr | ₹23.66 Cr | |
| Stockholders' equity | ₹-228.69 Cr | ₹876.64 Cr | ₹843.61 Cr | ₹842.05 Cr | ₹834.79 Cr | ₹834.84 Cr |
Trade receivables, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹106.76 Cr | ₹-108.43 Cr | ₹-423.46 Cr | ₹3.47 Cr | ₹-27.37 Cr | ₹16.68 Cr | |
| Investing cash flow | ₹-47.68 Cr | ₹1,282.57 Cr | ₹430.33 Cr | ₹6.66 Cr | ₹64.98 Cr | ₹-40.49 Cr |
| ₹-47.11 Cr | ₹-1,175.85 Cr | ₹-18.38 Cr | ₹-2.81 Cr | ₹-2.66 Cr | ₹-1.05 Cr | |
| Capital expenditure | — | ₹-17.51 Cr | ₹-40.95 Cr | ₹-82.88 Cr | ₹-50.31 Cr | ₹-54.09 Cr |
| End cash position | ₹52.08 Cr | ₹50.35 Cr | ₹39.85 Cr | ₹47.17 Cr | ₹82.13 Cr | ₹57.31 Cr |
Depreciation & amortization, Debt issued, Debt repaid, Capital expenditure have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Mar 24(11Q) | Jun 24 | Sep 24 | Dec 24 | Mar 25–Jun 26(6Q) |
|---|---|---|---|---|---|
| Promoter | 73.59% | 73.46% | 72.87% | 72.49% | 72.48% |
| Public | 26.41% | 26.54% | 27.13% | 27.51% | 27.52% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Panacea Biotec Limited | ₹2,278.53 Cr | ₹367.9 | — | 2.73 | -0.6% | 0.03 | +14.4% | -17.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 30
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
2 indices
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
Pharma stocks today, September 8: Sudeep Pharma, Strides and Panacea Biotec gain; Indoco Remedies falls
Business Upturn · 11 days ago